ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1547

A 4 Plus 2 Infusion Protocol of Rituximab Provides Long-Term Beneficial Effects in Patients with HCV-Associated Mixed Cryoglobulinemia with Membranoproliferative Nephritis and Severe Polyneuropathy

Dario Roccatello1, Savino Sciascia2, Simone Baldovino3 and Daniela Rossi1, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 3Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cryoglobulinemia, rituximab and vasculitis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Mixed cryoglobulinemia syndrome (MCs) is a systemic vasculitis characterized by multiple organ involvement due to the vascular deposition of immune-complexes, mainly the cryoglobulins. B cells expansion frequently triggered by HCV infection plays a central role in MCs. The long term effects of B-cells depletion in MCs are still on debate

Methods:

Twenty seven patients, (mean age 60.2 [range 35-78] years, HCV infection in 96% of cases) with symptomatic type-II MCs with systemic manifestations, including renal involvement (diffuse membranoproliferative glomerulonephritis in 15 cases), peripheral neuropathy (26 cases) and large skin ulcers (9 case, in 7 necrotizing) were considered eligible for Rituximab (RTX) therapy. RTX was administered at a dose of 375 mg/m2 on days 1, 8, 15 and 22. Two more doses were administered 1 and 2 months later. No other immunosuppressive drugs were added. Response was evaluated by assessing the changes in clinical signs, symptoms, laboratory parameters and electromyographic indices for a very long term follow-up (mean 54.3 months [12-96])

Results: Complete remission of pre-treatment active manifestations was observed in all the cases of skin purpuric lesions and non-healing vasculitic leg ulcers, and in 80% of the peripheral neuropathy, mainly paresthesias. A significant improvement in the clinical neuropathy disability score was observed. Electromyography examination revealed that the amplitude of compound motor action potential had increased.  Cryoglobulinemic nephropathy, observed in 15 patients, significantly improved during the follow-up starting from the second month after RTX (serum creatinine from 2.2±1.9SD to 1.6±1.2SD mg/dl, p≤.05; 24-hour proteinuria from 2.3±2.1SD to 0.9±1.9SD g/24h, p≤.05). Improvement of cryoglobulinemic serological hallmarks, such as cryocrit and low complement C4, were reported. The safety of RTX was confirmed by the absence of side effects recorded during the mean 54-month follow-up. Re-induction was performed in 9 relapsed cases (after a mean of 31.1 months, range 12-54) with resolutive beneficial effects

Conclusion:

In this open prospective study, RTX appeared to be effective and safe in the treatment of patients with MCs-associated neuropathy and membranoproliferative nephritis


Disclosure:

D. Roccatello,
None;

S. Sciascia,
None;

S. Baldovino,
None;

D. Rossi,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-4-plus-2-infusion-protocol-of-rituximab-provides-long-term-beneficial-effects-in-patients-with-hcv-associated-mixed-cryoglobulinemia-with-membranoproliferative-nephritis-and-severe-polyneuropathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.